2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On July 31, 2026, GoDaddy subsidiaries signed an amendment that replaces their existing $1.0 billion revolving credit facility with a new $1.2 billion facility. The filing says the new facility carries a stated maturity of July 31, 2031, and keeps the same leverage covenant as the prior facility, so the change mainly affects the company's borrowing capacity and financing terms.
New revolving credit facility of $1.2 billion replaces the existing $1.0 billion facility
Margin of 1.25% to 1.75% for term SOFR, EURIBOR or SONIA-based loans, and 0.25% to 0.75% for U.S. dollar base rate loans, both based on first lien net leverage ratio
Stated maturity of July 31, 2031, with a springing maturity tied to certain term loans or debt issuances above $500 million
Covenant requires a first lien net leverage ratio of no more than 5.75:1.00 when utilization is at least 40% of commitments
Reformation Inc. completed its initial public offering on July 31, 2026, selling 14,062,500 shares of common stock at $15.00 per share, including 4,583,679 shares sold by selling stockholders. The company said it received no proceeds from the selling stockholders' shares, and it reported aggregate gross proceeds of approximately $210.9 million before underwriting discounts, commissions and estimated offering expenses. Its amended and restated certificate of incorporation and bylaws took effect on the same date, which sets the governing rules for shareholders going forward.
IPO closed July 31, 2026: 14,062,500 shares at $15.00 per share
Includes 4,583,679 shares sold by selling stockholders; the company received no proceeds from those shares
Aggregate gross proceeds of approximately $210.9 million before underwriting discounts and estimated expenses
Amended and restated certificate of incorporation and bylaws effective July 31, 2026
Stoke Therapeutics filed a prospectus supplement on August 3, 2026, covering the offer and sale of up to $200 million of common stock through Cantor Fitzgerald under an existing May 2022 sales agreement. The filing makes new share issuance possible, which could dilute existing shareholders, but the filing itself does not state how many shares have been sold or at what prices.
Prospectus supplement filed August 3, 2026 covers up to $200,000,000 of Placement Shares.
Sales run through Cantor Fitzgerald & Co. under the Controlled Equity Offering sales agreement dated May 20, 2022.
Offering is made under an automatic shelf registration statement (Form S-3ASR, File No. 333-294402) filed March 18, 2026.
Fenwick & West LLP legal opinion is filed as Exhibit 5.1.
Nuwellis, Inc. sold 1,310,890 common shares at $2.59 per share in a registered direct offering, with gross proceeds expected to be about $3.4 million before placement agent fees and expenses. The offering closed on August 3, 2026, and investors also received warrants to buy up to 1,310,890 more shares at $2.59, which adds potential future dilution for existing shareholders.
Registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds expected to be about $3.4 million before fees and expenses
Concurrent private placement of warrants to buy up to 1,310,890 shares at $2.59, exercisable immediately with a five-year term from registration effectiveness
Placement agent Ladenburg Thalmann & Co. Inc. receives a cash fee of 9.0% of gross proceeds plus warrants equal to 3.0% of shares issued
Company separately received $3.1 million from warrant exercises tied to its June 2026 public offering, according to the press release
On July 31, 2026, Alzamend Neuro agreed to sell up to $25 million of its newly designated Series D convertible preferred stock to Ault Lending, LLC, which the filing says is an affiliate of the company. The company sold $7.5 million of preferred at an initial closing, and the purchaser agreed to buy $2.5 million more later, with up to $15 million in further tranches permitted. Conversion into common stock could dilute existing shareholders, and the company must seek stockholder approval for conversion shares above the Nasdaq 19.99% limit.
Initial tranche: 7,500 Series D preferred shares sold for $7.5 million on July 31, 2026; second tranche of $2.5 million agreed
Conversion price is the greater of a $0.2668 floor and 80% of the lowest closing bid in the prior five trading days, capped at $2.00 per share
Company must file a resale registration statement by the earlier of five days after its 10-K filing or August 15, 2026, and seek stockholder approval for conversion shares above 19.99% of common stock outstanding
Registration default would trigger cash payments to the purchaser of 2% of stated value monthly, capped at 15%
Amneal Pharmaceuticals LLC, a subsidiary of Amneal Pharmaceuticals, Inc., entered into Amendment No. 3 to its Term Loan Credit Agreement on August 3, 2026, reducing the interest rate margin on its term loans by 50 basis points. The company estimates annualized cash interest savings of approximately $12 million compared with the prior agreement, based on amounts outstanding before the amendment.
Existing term loans converted into new term loans with an aggregate principal amount of $2.039 billion
A new $45.2 million term loan was incurred, with proceeds used to prepay remaining existing term loans at par
Margin reduced to 1.50% for base rate loans and 2.50% for SOFR-based loans; stated maturity remains August 1, 2032
Estimated annualized cash interest savings of approximately $12 million; no prepayment premium on a repricing after February 3, 2027
Autolus Therapeutics signed a Note Purchase Agreement on July 30, 2026, for a senior secured notes facility of up to $250.0 million, with $75.0 million issued at closing. The company also issued Perceptive a warrant for up to 3,500,000 ADSs, which adds potential future share dilution, and agreed to file a resale registration statement within 45 calendar days of closing.
Tranche 1 notes of $75.0 million issued July 30, 2026; up to $175.0 million more available in three tranches
Interest is a margin of 6.75% to 7.25% plus the greater of one-month term SOFR and 3.50%; maturity July 30, 2031
Warrant for up to 3,500,000 ADSs at $1.9314 per ADS, expiring July 30, 2036; notes are secured by substantially all company and subsidiary assets
Financial covenants require minimum liquidity of $12.5 million to $50.0 million and minimum Consolidated Net Revenue
GameStop agreed on August 2, 2026 to exchange about $1.4 billion of its convertible senior notes held by a limited number of institutional holders for Class A common stock, with no cash proceeds to the company. The exchange would reduce long-term debt by about $1.4 billion, but the number of new shares is not yet set and will issue to holders in a private placement, which could dilute existing shareholders.
Exchange covers about $400 million of 2030 Notes and $1.0 billion of 2032 Notes; about $1.1 billion of 2030 Notes and $1.7 billion of 2032 Notes remain outstanding after closing.
Share count depends on the average volume-weighted average price over a 35 trading day period starting August 3, 2026, subject to a per share price floor.
Closing is expected on or about September 23, 2026, and either party may terminate if it has not closed by September 30, 2026.
Noteholders may buy, sell or hedge GameStop shares during the process, which could move the stock price.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.